How many patients has Curex treated?

More than 50,000 patients have been treated with at-home allergy immunotherapy through Curex, in all 50 states, for environmental and food allergies.

Has Curex published peer-reviewed research?

Yes, two studies in 2026. An outcomes study of 2,897 adults on environmental-allergy drops appeared in Frontiers in Allergy in June (PMID 42358593), and a safety study of 13,584 patients and 18,398 patient-years appeared in Allergy, Asthma & Clinical Immunology in October (doi:10.1186/s13223-026-01079-1).

How well do Curex allergy drops work?

In the 2,897-patient study, 28% of patients reached a symptom-score improvement of at least 30 points by 12 months and 45% by 24 months. Improved quality of life was reported by 81.4% at 12–18 months, rising to 90.7% at 30–36 months, and the share cutting allergy-medication use by 75–100% rose from 18.2% to 31.3% over the same period.

How safe are Curex allergy drops?

In the 13,584-patient safety study, side effects were predominantly mild: 7.76% reported a mild event, 1.95% a moderate event and 0.09% a severe event, with no deaths. Two patients reported anaphylaxis or a severe allergic reaction, one judged treatment-related, and 1.8% had stopped because of side effects by 36 months.

Who funded the studies?

Curex funded both studies. Statistical analysis was performed independently by Arx Sciartis, and both papers were peer-reviewed before publication.

Do the results apply to food-allergy drops or allergy shots?

The outcomes study covered adults on environmental-allergy drops. The safety study covered environmental-allergy drops, including 113 patients who also received food-allergy drops. Neither studied allergy shots. Your clinician will explain what to expect from your own treatment.

Curex guide

Curex by the numbers: 50,000+ patients and two peer-reviewed studies

More than 50,000 patients treated at home, a peer-reviewed study of outcomes in 2,897 adults, and a peer-reviewed safety study covering 18,398 patient-years. Here are the results.

Short answer

Curex has treated more than 50,000 patients with at-home allergy immunotherapy and has published two peer-reviewed studies of its patients in 2026. The first (Frontiers in Allergy, PMID 42358593) followed 2,897 adults on environmental-allergy drops: 45% reached a symptom improvement of at least 30 points by 24 months, 81–94% reported better quality of life after the first year, more than 90% took their drops on at least 20 days a month, and no anaphylaxis was reported. The second (Allergy, Asthma & Clinical Immunology, doi:10.1186/s13223-026-01079-1) reviewed 13,584 patients and 18,398 patient-years of home treatment: side effects were predominantly mild, there were no deaths, and 1.8% stopped because of side effects by 36 months.

At a glance

Curex in numbers

patients treated with at-home allergy immunotherapy: 50,000+patients treated with at-home allergy immunotherapy
peer-reviewed studies of Curex patients, both published in 2026: 2peer-reviewed studies of Curex patients, both published in 2026
adults followed for symptom outcomes in the first study: 2,897adults followed for symptom outcomes in the first study
patient-years of home treatment reviewed for safety in the second: 18,398patient-years of home treatment reviewed for safety in the second

Curex company facts

Curex company facts
Fact	Curex	Detail
Patients served	More than 50,000	At-home allergy immunotherapy for environmental and food allergies.
Founded	2019	Offices in New York and Miami.
Service footprint	All 50 U.S. states	Eligibility is confirmed for each patient at enrollment.
Program pricing	Current Curex program prices	Environmental-drop, food-drop and allergy-shot plans each have their own rate.
Testing options	Three	Local lab, at-home phlebotomist, or self-collection kit; previous test results can also be reviewed.
Minimum ages	2 for food drops; 5 for environmental drops	A physician assessment is required for every patient.
Prescription supply	Three months per shipment	Month-to-month terms; remaining payments for treatment already shipped are collected after cancellation.
Typical intake to first shipment	5–10 days	Typical timing from intake to the first prescription shipment.
Peer-reviewed research	Two studies, 2026	[Frontiers in Allergy](${STUDY}) (outcomes) and [Allergy, Asthma & Clinical Immunology](${SAFETY}) (safety).

Curex offers physician-prescribed environmental and food drops, at-home environmental allergy shots, asthma care, eczema treatment and Quickie nasal spray, with ongoing physician and care-manager supervision online.

Study 1 · Frontiers in Allergy, June 2026

Outcomes: 2,897 adults on Curex environmental-allergy drops

The first study, published June 10, 2026 in Frontiers in Allergy, followed 2,897 adults treated with personalized sublingual immunotherapy for environmental allergies through Curex between 2020 and 2025 (PubMed, full text). It tracked symptoms, medication use, quality of life, adherence and side effects for up to three years and more.

Symptom response rose steadily with time on treatment: by 24 months, 45% of patients had reached a symptom-score improvement of at least 30 points, and by 30–36 months more than 90% reported a better quality of life. More than 90% took their drops on at least 20 days a month, and no anaphylaxis or eosinophilic esophagitis was reported.

Who was in the outcomes study

From the study methods and results.

Who was in the outcomes study
Measure	Reported number	What it represents
Registered platform accounts	27,257	Accounts seeking environmental- or food-allergy care at the time of manuscript preparation.
At least one treatment cycle	17,934	Users who received a treatment cycle.
At least one online survey	10,756	Users with any treatment survey.
Included environmental-allergy cohort	2,897 adults	Confirmed IgE sensitization, at least four 3-month prescription shipments, and qualifying baseline and follow-up ART surveys.
Baseline survey timing	Before treatment or within 3 months of first shipment	The starting point for each patient’s symptom score.
Follow-up eligibility	At least 12 months after initiation	A qualifying later survey was required.
Median survey follow-up	20 months; IQR 15.0–24.8	Time from first shipment to last submitted survey.
Median shipment-based treatment duration	26.0 months; IQR 22.4–34.1	First-to-last shipment interval plus the final 3-month cycle.
Mean age / women	39.0 years / 1,527 of 2,897 (52.7%)	Adult study demographics.
Reported physician-diagnosed asthma	732 of 2,897 (25.3%)	The asthma subgroup.

Source: Tharpe et al., Frontiers in Allergy 2026, Methods and Results.

How symptom response was measured

The Allergy Response Tracker (ART) asks about six domains: nasal congestion, sneezing, watery eyes, sleep disruption, limitations on daily activities, and overall symptom control. Answers are scored 0–100 and averaged, with higher scores meaning worse symptoms. The mean starting score was 49.9 points, and the study counted a patient as a responder after an improvement of at least 30 points — a demanding bar of more than half the average starting score. Methods and Table 3.

The study reports four response measures, from reaching the threshold at least once to holding it at every later survey. Each is a Kaplan–Meier estimate over time, shown below.

Symptom response at 12 and 24 months

All four measures start with the 2,897-patient cohort. Figure 4 and the time-to-response results.

Symptom response at 12 and 24 months
Measure	Definition	12 months (95% CI)	24 months (95% CI)
Response at least once	At least one assessment with a ≥30-point improvement from baseline.	28% (27–30%)	45% (43–48%)
Response with ≤1 rebound	Threshold reached and lost no more than once when ≥3 follow-up assessments after first response were available; otherwise no rebound allowed.	14% (13–15%)	26% (24–27%)
Response without rebound	Threshold reached and maintained at every subsequent available assessment.	9% (8–10%)	20% (19–22%)
Sustained response	The ≤1-rebound rule plus the ≥30-point improvement observed on at least two assessments.	14% (13–15%)	18% (17–20%)

For the response-at-least-once curve, Figure 4 lists 2,897 patients initially at risk, 2,072 at 12 months and 475 at 24 months. The study also reports a model-predicted 10.1-point improvement from baseline by 6 months at the mean starting severity.

Quality of life over time

Patients were asked whether their quality of life had improved since starting treatment. Figure 7C.

Quality of life over time
Time since first shipment	Patients answering	Reporting improved quality of life (95% CI)
12–18 months	2,391	81.4% (79.8–82.9%)
18–24 months	1,378	85.7% (83.8–87.5%)
24–30 months	668	89.7% (87.1–91.8%)
30–36 months	281	90.7% (86.8–93.6%)
≥36 months	52	94.2% (84.4–98.0%)

Medication use, adherence and side effects

Medication use In Figure 7A, 18.2% reported a 75–100% reduction in allergy-medication use at 12–18 months (n=2,391), rising to 26.2% at 24–30 months (n=668) and 31.3% at 30–36 months (n=281). Change medication only with your clinician.
Adherence More than 90% reported taking drops on at least 20 days per month across every study interval. Figure 7D gives interval counts of 2,312 (0–6 months), 1,841 (6–12), 2,391 (12–18), 1,378 (18–24), 668 (24–30), 281 (30–36), and 52 (≥36).
Discontinuation Forty-two of the 2,897 included patients met the paper’s survey-based discontinuation criteria.
Side effects Table 4 reports at least one Grade I event in 339/2,897 patients (11.7%), Grade II in 108/2,897 (3.73%), and Grade III in 24/2,897 (0.83%); a patient can appear in more than one grade. No Grade IV or V events, anaphylaxis, or eosinophilic esophagitis were reported.

About the outcomes study

The authors note that the study was retrospective and single-arm, without a placebo or comparison group; that it included patients with at least a year of treatment and qualifying surveys; that symptoms were self-reported on the ART, which has not been externally validated; and that seasonal variation could not be fully adjusted for. The study was funded by Curex; statistical analysis was performed independently by Arx Sciartis.

Cite as: Tharpe C et al. Front Allergy. 2026;7:1865860. doi:10.3389/falgy.2026.1865860. PMID 42358593. PMCID PMC13290930.

Study 2 · Allergy, Asthma & Clinical Immunology, October 2026

Safety: 13,584 patients and 18,398 patient-years

The second study, published October 21, 2026, reviewed every reported side effect among Curex patients treated with sublingual drops at home from November 2020 to May 2026 (full paper). Side effects were predominantly mild, and serious reactions were rare.

reported a mild (Grade I) side effect; 1.95% moderate (Grade II): 7.76%reported a mild (Grade I) side effect; 1.95% moderate (Grade II)
reported a severe (Grade III) side effect: 0.09%reported a severe (Grade III) side effect
deaths: 0deaths
stopped because of side effects by 36 months: 1.8%stopped because of side effects by 36 months

Safety study results

Safety study results
Measure	Result
Patients included	13,584, from 29,675 who received at least one shipment (144,972 shipments)
Exposure	18,398 adherence-adjusted patient-years; median treatment 17.1 months, up to 59 months
Side effects, all grades	8 per 100 patient-years (95% CI 7.60–8.42), mostly Grade I
Most common	Nasal congestion (1.07% mild), sneezing (0.71%), throat irritation (0.57%), runny nose (0.53%), cough (0.46%)
Grade IV	1 patient (0.01%): cardiac arrest with a pre-existing heart-rhythm disorder, unrelated to treatment
Anaphylaxis or severe allergic reaction	2 patients (0.01%); 1 treatment-related
New eosinophilic esophagitis	5 patients (0.04%); 2 suspected treatment-related
Stopped because of side effects	1.4% of patients overall; 1.1% by 12 months, 1.5% by 24, 1.8% by 36

The full explanation — side effects by grade, anaphylaxis and EoE, and how Curex keeps home treatment safe — is on Are allergy drops safe?.

About the safety study

The authors note that side effects were self-reported through quarterly surveys without outside verification, that the analysis included patients who completed at least one survey, that some reported symptoms overlap with allergy symptoms themselves, and that the data come from one telemedicine platform. The study was funded by Curex; statistical analysis was performed independently by Arx Sciartis.

Cite as: Tharpe C, Mardaga K, Davidson J, Solow C, Kakaulin G, Kruzick T, Herold J, Snyder M, Hakobyan B. Real-world safety of personalized telemedicine-delivered sublingual immunotherapy: reported adverse events across 18,398 patient-years. Allergy Asthma Clin Immunol. 2026. doi:10.1186/s13223-026-01079-1.

Clinical and regulatory context

Personalized allergy drops are compounded for each patient and prescribed off-label, made from FDA-approved allergenic extracts — the same extracts used in allergy shots. Allergy drops are part of the American Academy of Otolaryngology’s standard of care and the standard of care in many EU countries. FDA: compounded drugs.

People with a history of anaphylaxis or uncontrolled asthma should have an in-person allergy evaluation first, and immunotherapy is not started during pregnancy (2024 inhalant-immunotherapy guideline). Food challenges require direct medical supervision and are never done at home.

Frequently Asked Questions

General information, not individualized medical advice. Your treating clinician decides eligibility, treatment and dosing. For trouble breathing, throat swelling, faintness or a suspected severe allergic reaction, follow your prescribed emergency plan and call 911.

Sources

Written by Curex editorial team.